How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

Dual AAV Gene Therapy: Genetic Engineering Solutions for Large Gene Delivery

Adeno-associated virus (AAV) vectors have become a cornerstone of modern gene therapy, enabling multiple FDA-approved treatments for inherited disorders. Despite these advances, the clinical utility of AAV is fundamentally constrained by its limited packaging capacity of approximately 4.7–5 kb, which precludes direct gene replacement for many large disease-causing genes. Dual AAV gene therapy has emerged as an innovative strategy to overcome this barrier by using two coordinated AAV vectors that function together to deliver therapeutic genetic payloads beyond the capacity of a single vector. By enabling functional correction of genes previously considered inaccessible, this approach has expanded the therapeutic landscape while simultaneously introducing new biological, engineering, and translational considerations.

Defining Dual AAV Therapy

Dual AAV therapy refers to a class of gene therapy strategies that employ the simultaneous administration of two AAV vectors to achieve a therapeutic effect unattainable by a single vector. In contrast to conventional single-vector approaches, dual AAV systems rely on coordinated delivery and expression of complementary genetic components that interact at the level of DNA, RNA, or protein to produce a functional therapeutic outcome ^{(1,2, 3, 4)}. Although each vector individually conforms to the strict packaging limits of AAV, their combined activity enables treatment of diseases caused by genes that exceed the capacity of standard AAV vectors. This shared reliance on cooperative function, rather than expanded vector capacity, represents the unifying principle underlying all dual AAV strategies.

Major Mechanistic Classes of Dual AAV Therapy

Dual AAV strategies encompass a diverse set of mechanistic designs that differ in how the two vectors cooperate to achieve therapeutic efficacy. While unified by the use of two independently packaged AAV vectors, these approaches can be broadly categorized based on the biological level at which functional correction occurs and the specific problem being addressed. In general, dual AAV systems aim either to reconstruct a large gene product, restore a missing biological function through cooperative protein activity, or enable coordinated regulation across tissues or molecular pathways. The principal mechanistic classes of dual AAV therapy are summarized in Table 1.

Table 1. Major mechanistic classes of dual AAV therapy

Mechanistic class	Core principle	Level of interaction	Representative features
Gene reconstitution strategies ^(5,6)	Reassembly of a full-length gene or protein from two partial sequences	DNA, RNA, or protein	Includes trans-splicing, homologous recombination, and intein-mediated protein splicing; requires efficient co-delivery and intracellular reconstitution
Functional complementation strategies ⁽⁷⁾	Cooperative action of two independently expressed proteins or domains	Protein or pathway level	Each vector encodes a distinct functional component; physical fusion is not required; therapeutic effect emerges from biological synergy
Multi-tissue or multi-compartment targeting ⁽⁷⁾	Differential targeting of vectors to distinct tissues or cellular compartments	Tissue or cellular level	Distinct promoters or capsids are used to address complex, multi-organ disease pathology
Regulatory dual-vector systems ^{(8, 9,10)}	Separation of therapeutic payload and regulatory machinery	Transcriptional or genomic level	One vector encodes the therapeutic gene, while the second delivers transcriptional modulators or genome-editing components

Advantages and Limitations of Dual AAV Therapy

Dual AAV therapy offers several important advantages that extend the therapeutic scope of AAV-based gene delivery beyond what is achievable with single-vector approaches. Most notably, the use of two coordinated vectors circumvents the intrinsic AAV packaging limitation, enabling treatment of diseases caused by large genes that cannot be accommodated within a single AAV genome. Genes encoding proteins such as dystrophin (DMD, ~14 kb), laminin-α2 (LAMA2, >9 kb), and dysferlin (DYSF, ~6.5 kb) are incompatible with single AAV vectors in their full-length forms. Dual AAV strategies therefore provide a path toward restoring native or near-native protein function in these settings.

In addition, certain dual AAV designs may reduce immunogenic risk, particularly when they avoid expression of large, non-self transgene products and instead rely on smaller or endogenously derived protein domains. The modular nature of dual AAV systems also enables mutation-independent therapeutic strategies that can be applied across genetically heterogeneous patient populations, as demonstrated in disorders involving structural or extracellular matrix defects. Furthermore, dual AAV approaches allow flexible targeting of complex diseases affecting multiple tissues, such as skeletal muscle and peripheral nerve, by combining vectors with distinct promoters, capsids, or expression profiles.

Despite these advantages, dual AAV therapy introduces additional layers of biological and translational complexity. The requirement to manufacture, characterize, and regulate two vectors as a single therapeutic product poses significant challenges for large-scale production and clinical development. Many dual AAV approaches, particularly those based on intracellular gene or protein reconstitution, depend on efficient co-delivery of both vectors to the same cell, which can limit robustness and consistency of therapeutic expression. Differences in vector uptake, expression kinetics, or stability may also lead to imbalanced stoichiometry between the two components, potentially reducing efficacy or increasing variability. Functional complementation strategies partially mitigate these limitations by relaxing the requirement for strict co-transduction, allowing therapeutic benefit to emerge at the tissue or pathway level rather than within individual cells.

Major Dual AAV Strategies Across Diseases

Dual AAV strategies have been explored across a wide range of indications, including muscular dystrophies, inherited retinal diseases, metabolic disorders, and neurodegenerative conditions (Table 2). Early efforts focused primarily on gene reconstitution approaches, whereas more recent strategies increasingly emphasize functional and pathway-level complementation.

Table 2. Major dual AAV strategies across diseases

Disease / Indication	Target Gene or Pathway	Dual AAV Strategy Type	Mechanism
Duchenne muscular dystrophy ⁽¹¹⁾	DMD	Split gene (intein, overlap)	Intracellular dystrophin reconstitution
Dysferlinopathy ⁽¹²⁾	DYSF	Overlapping dual AAV	Homologous recombination
Stargardt disease ⁽¹³⁾	ABCA4	Dual AAV trans-splicing	Full-length ABCA4 expression
CEP290 retinal dystrophy ⁽¹⁴⁾	CEP290	Dual AAV splitting / editing	Partial protein restoration
LAMA2-related muscular dystrophy ⁽¹⁵⁾	Laminin-2X1 function	Functional complementation	ECM reassembly via linker proteins
Spinal muscular atrophy (experimental) ⁽¹⁶⁾	SMN pathway	Regulatory dual AAV	Expression modulation

Conclusions

Dual AAV therapy expands the therapeutic capacity of AAV vectors by embracing modularity, biological insight, and system-level correction rather than relying on single-vector gene replacement. As these strategies progress toward clinical application, continued innovation in vector engineering, dose optimization, immune modulation, and patient selection will be essential. The growing body of preclinical evidence, particularly in mouse models, provides optimism that dual AAV gene therapy will ultimately enable transformative treatments for LAMA2-related muscular dystrophy and other currently incurable genetic diseases caused by mutations in large genes.

Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI).

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.